Background
obesity, inflammation, cardiometabolic disease, MetS, weight loss
OBESITY, INFLAMMATION, SECONDARY
Identifying and reducing cardiometabolic risks driven by obesity remains a major healthcare challenge [MetS denotes a cluster of common risk factors and was intended as an early measure for cardiometabolic disease risk [High-sensitivity C-reactive protein (hsCRP) is an established biomarker of inflammation [Exercise and glucagon-like peptide–1 receptor agonists (GLP-1 RAs) may be different strategies in the primary and secondary prevention of MetS, abdominal fat, and inflammation [A meta-analysis has shown that moderate-to-vigorous aerobic exercise for at least 12 weeks can improve the factors of MetS [The GLP-1 RA, liraglutide, approved for obesity therapy, induces weight loss and improves glycemic control and cardiovascular risk factors (e.g., lipid profile and blood pressure) [We recently showed that a diet-induced 12% weight loss was maintained after one year with either exercise or liraglutide treatment. Combining the two treatments led to additional weight loss, while the placebo group regained body weight [